This allows very fine dose adjustments, but it also introduces measurement and sterility risks
Retrieved from That Diabetic Girl
Elimination : The terminal elimination half-life is approximately 6 days, supporting once-weekly dosing
Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]
Orskov, C., Rabenhoj, L., Wettergren, A., Kofod, H